Donoghue Forlines LLC Invests $2.83 Million in Cencora, Inc. $COR

Donoghue Forlines LLC acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 9,428 shares of the company’s stock, valued at approximately $2,827,000.

Several other large investors also recently bought and sold shares of the business. Invesco Ltd. lifted its stake in Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after acquiring an additional 1,364,433 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in shares of Cencora by 4,459.6% in the first quarter. T. Rowe Price Investment Management Inc. now owns 997,233 shares of the company’s stock worth $277,321,000 after acquiring an additional 975,362 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Cencora by 8.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock valued at $2,682,821,000 after purchasing an additional 787,858 shares during the last quarter. Nuveen LLC bought a new position in Cencora during the first quarter valued at approximately $181,284,000. Finally, Caisse DE Depot ET Placement DU Quebec boosted its holdings in Cencora by 144.4% in the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 743,072 shares of the company’s stock worth $206,641,000 after purchasing an additional 439,008 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the sale, the chief executive officer owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 41,544 shares of company stock valued at $12,230,941 in the last ninety days. 10.80% of the stock is currently owned by insiders.

Cencora Stock Up 0.5%

NYSE COR opened at $365.06 on Friday. The stock’s 50-day moving average price is $319.97 and its 200-day moving average price is $301.57. The company has a market capitalization of $70.78 billion, a P/E ratio of 37.56, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 52 week low of $223.92 and a 52 week high of $366.17.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the prior year, the firm posted $3.34 EPS. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 14th will be paid a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is presently 30.19%.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Mizuho boosted their target price on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. UBS Group lifted their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a report on Friday, November 7th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. TD Cowen raised their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Evercore ISI set a $400.00 price target on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus price target of $371.09.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.